Rallybio Corp 8-K

What Happened

• Rallybio Corporation announced on March 31, 2026 that Steven Ryder, M.D., who had served as Chief Medical Officer since January 2019, left the company effective immediately.
• Rallybio and Dr. Ryder signed a Separation Agreement providing that he will receive the severance payments and benefits due under his existing employment agreement for a termination without cause (the Initial Severance Amounts). Additional severance tied to Rallybio’s pending merger with Candid Therapeutics, Inc. will be paid upon closing, reduced by the Initial Severance Amounts already paid.
• Any restricted stock, stock options and other equity awards granted to Dr. Ryder will remain outstanding and may vest under the terms of the Merger Agreement; they will be exercisable until 90 days after the merger closes. The Merger Agreement is dated March 1, 2026.

Key Details

• Date of filing/announcement: March 31, 2026.
• CMO tenure: Steven Ryder served as Rallybio’s Chief Medical Officer since January 2019.
• Severance structure: Initial severance per existing employment agreement; additional change-of-control severance payable after merger closing, offset by amounts already paid.
• Equity treatment: Awards remain eligible to vest per the Merger Agreement and are exercisable through 90 days post-closing.
• The full Separation Agreement will be filed with Rallybio’s Form 10-Q for the quarter ended March 31, 2026.

Why It Matters

• Executive change: The departure of the CMO may affect leadership for clinical and development programs; investors should watch for announcements about a replacement and any near-term impact on program timelines.
• Financial impact: The Separation Agreement creates a defined severance obligation and potential additional payments tied to the pending merger; the exact dollar amounts will be disclosed in the forthcoming 10-Q.
• Merger linkage: Severance and equity vesting are explicitly tied to the pending business combination with Candid Therapeutics, so progress or changes in that merger may affect Rallybio’s obligations and executive incentives.
• Next steps for investors: Review the upcoming Form 10-Q for the complete Separation Agreement terms and monitor company updates on the CMO replacement and the status of the Candid merger.